FYB1 and diffuse large B-cell lymphoma: Specifically, ATAD3A, CALR, CWF19L1, GALT, MAGEA9, MAPKI8IP3, PSLNR, SEPTIN7P13, SLC19A1 and SLC38A5 resulted up-regulated in non-responder patients, while high expression levels of EBF1, EDNRA, CCDC18, CCDC186, FYB, MALAT1, MIS18BP1, MYO6, THRAP3 and TOP1, characterized responder DLBCL patients (Figure 1C).